Reversal of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole and a 5-HT6 Receptor Antagonist: Comparison Among Antipsychotics
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Currently accepted treatments for schizophrenia can effectively control positive symptoms but have limited impact on cognitive deficits in schizophrenia. The purpose of these experiments was to address this unmet need by characterizing the effects of classical and second-generation antipsychotics on cognitive impairments associated with schizophrenia. An additional aim was to characterize the part(s) of the pharmacological profile of drugs that were important to reverse deficits. Cognitive deficits were assessed using a frontally mediated attentional set-shifting task in rats that is analogous to tasks used in humans and nonhuman primates that assess executive function. Mirroring findings in patients with schizophrenia, the classical antipsychotic haloperidol was ineffective in treating set-shifting deficits induced by subchronic treatment with phencyclidine (PCP). Similarly, second-generation antipsychotics, risperidone, clozapine, and olanzapine were ineffective. In contrast, selected doses of sertindole and the 5-HT(6) receptor antagonist SB 271046 attenuated PCP-induced set-shifting deficits. Finally, the 5-HT(2A) receptor antagonist M100907 was without effect. Further examination revealed that repeated treatment (21 days) with sertindole, but not olanzapine, also was effective in reversing the executive function deficit. These data suggest that the combination of 5-HT(6) antagonistic activity and the absence of antimuscarinic activity may represent key characteristics of the pharmacological profile for improved antipsychotic drugs for schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In PCP-treated rats, the 5-HT6 receptor antagonist, SB 271046, and sertindole, a second generation antipsychotic that acts as an antagonist on several neurotransmitter receptors, with high affinity for the 5-HT6 receptor, reduced the PCP-induced deficit in set-shifting (Idris et al 2010, Rodefer et al 2008).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Rodefer et al 2008
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516 · cited 1×
“Unlike psychotic symptoms, cognitive deficits demonstrate a robust inverse association with community functioning and illness outcome (Addington and Addington, 1999; Green, 1996; Harvey et al, 1999).”
BackgroundGreen, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999 · cited 1×
“However, Kraepelin’s characterization of schizophrenia from over a century ago included descriptions of cognitive deficits (Kraepelin, 1904), and these have gained greater attention in the treatment literature during the past decade (Green et al, 2000; Weinberger and Gallhofer, 1997).”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 2×
“…we employed the well-validated subchronic phencyclidine (PCP)-administration paradigm (Jentsch and Roth, 1999; Cochran et al, 2003; Egerton et al, 2005; Abdul-Monim et al, 2006, 2007) to produce enduring cognitive deficits similar to those observed in schizophrenia (Javitt and Zukin, 1991).”
MethodDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527 · cited 1×
“Indeed, different regions of prefrontal cortex mediate extradimensional attentional shifts and reversal learning (Birrell and Brown, 2000, McAlonan and Brown, 2003, Dias et al, 1996).”
BackgroundMedial Frontal Cortex Mediates Perceptual Attentional Set Shifting in the Rat
Birrell, J. M., & Brown, V. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04320.2000 · Cited by 1,421 · cited 5×
“The set-shifting task adapted for rodents uses olfactory and tactile stimuli, rather than the visual stimuli used for testing of nonhuman primates and humans (Birrell and Brown, 2000).”
BackgroundMethodInfluentialJentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314 · cited 2×
“In addition, we employed the well-validated subchronic phencyclidine (PCP)-administration paradigm (Jentsch and Roth, 1999; Cochran et al, 2003; Egerton et al, 2005; Abdul-Monim et al, 2006, 2007) to produce enduring cognitive deficits similar to those observed in schizophrenia (Javitt and Zukin,…”
MethodKeefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065 · cited 2×
“Depending on the type of cognitive domain measured, second-generation antipsychotics have been reported to produce improvement (Mortimer 1997; Meltzer and McGurk, 1999; Keefe et al, 2007), no effect (Hoff et al, 1996; Meltzer and McGurk, 1999), and impairment (Goldberg et al, 1993).”
BackgroundMethodThe Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020 · cited 5×
“…et al, 2004; Remillard et al, 2005; Lee et al, 2007) or slightly effective, as measured by Wisconsin Card Sorting Test (Meltzer and McGurk, 1999; Harvey et al, 2005), and olanzapine produces effects in the same range as risperidone (Meltzer and McGurk, 1999; Bilder et al, 2002; Keefe et al, 2007).”
BackgroundMethodInfluentialVerapamil: A Review of its Pharmacological Properties and Therapeutic Use1
Singh, B. N., Ellrodt, G., & Peter, C. T. (1978) · Drugs · doi:10.2165/00003495-197815030-00001 · Cited by 832
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715 · cited 3×
“Clozapine has weaker DA D2 in vivo binding potency, but the selected doses examined were within behaviorally active levels, and further dose increase leads to marked sedation (see Arnt and Skarsfeldt, 1998).”
BackgroundSelf-citationOrbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat
McAlonan, K., & Brown, V. J. (2003) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.09.019 · Cited by 618 · cited 1×
“Indeed, different regions of prefrontal cortex mediate extradimensional attentional shifts and reversal learning (Birrell and Brown, 2000, McAlonan and Brown, 2003, Dias et al, 1996).”
BackgroundBilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538 · cited 1×
“…et al, 2004; Remillard et al, 2005; Lee et al, 2007) or slightly effective, as measured by Wisconsin Card Sorting Test (Meltzer and McGurk, 1999; Harvey et al, 2005), and olanzapine produces effects in the same range as risperidone (Meltzer and McGurk, 1999; Bilder et al, 2002; Keefe et al, 2007).”
MethodGoldberg, T. E., Goldman, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., Woerner, M. G., Schooler, N. R., Kane, J. M., & Robinson, D. G. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1115 · Cited by 394 · cited 1×
“Recently, it has been noted that meaningful cognitive enhancement for individuals with schizophrenia will not likely come from traditional medications (Green, 2007) and even instances where positive effects are reported may be due to practice effects (Goldberg et al, 2007).”
BackgroundNeurocognitive and Social Functioning in Schizophrenia
Addington, J., & Addington, D. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033363 · Cited by 361 · cited 1×
“Unlike psychotic symptoms, cognitive deficits demonstrate a robust inverse association with community functioning and illness outcome (Addington and Addington, 1999; Green, 1996; Harvey et al, 1999).”
BackgroundComparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage
Pantelis, C., Barber, F. Z., Barnes, T. R. E., Nelson, H. E., Owen, A. M., & Robbins, T. W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00156-x · Cited by 346 · cited 1×
“Certainly, no one animal protocol can effectively model a disease as complex and heterogeneous as schizophrenia, and previous reports (Pantelis et al, 1999) suggest that individuals with schizophrenia can demonstrate impairment on multiple aspects of cognition, including some nonEDS problems, an…”
Woolley, M., Marsden, C., & Fone, K. (2004) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007043482561 · Cited by 302 · cited 1×
“…and risperidone vs sertindole, we performed an experiment exploring the profiles of a selective 5-HT2A (M100907; Zhang and Bymaster, 1999) and 5-HT6 antagonist (SB 271046; Lacroix et al, 2004; Woolley et al (2004)) at dose levels shown to be effective in relevant mechanistic in vivo models.”
MethodThe Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia
Goldberg, T. E., Greenberg, R. D., Griffin, S. J., Gold, J. M., Kleinman, J. E., Pickar, D., Schulz, S. C., & Weinberger, D. R. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.1.43 · Cited by 289 · cited 1×
“Depending on the type of cognitive domain measured, second-generation antipsychotics have been reported to produce improvement (Mortimer 1997; Meltzer and McGurk, 1999; Keefe et al, 2007), no effect (Hoff et al, 1996; Meltzer and McGurk, 1999), and impairment (Goldberg et al, 1993).”
BackgroundClozapine: A Review of its Pharmacological Properties, and Therapeutic Use in Schizophrenia
Fitton, A., & Heel, R. C. (1990) · Drugs · doi:10.2165/00003495-199040050-00007 · Cited by 278 · cited 1×
“Novel antipsychotic compounds (second-generation or ‘atypical’ antipsychotics) such as clozapine (Fitton and Heel, 1990), olanzapine (Fulton and Goa, 1997), and sertindole (Kane and Tamminga, 1997; Azorin et al, 2006) have some beneficial effect on negative symptoms and reduced potential to produce…”
BackgroundFulton, B., & Goa, K. L. (1997) · Drugs · doi:10.2165/00003495-199753020-00007 · Cited by 250 · cited 2×
“Novel antipsychotic compounds (second-generation or ‘atypical’ antipsychotics) such as clozapine (Fitton and Heel, 1990), olanzapine (Fulton and Goa, 1997), and sertindole (Kane and Tamminga, 1997; Azorin et al, 2006) have some beneficial effect on negative symptoms and reduced potential to produce…”
BackgroundBrewer, W. J., Wood, S. J., Phillips, L. J., Francey, S. M., Pantelis, C., Yung, A. R., Cornblatt, B., & McGorry, P. D. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj077 · Cited by 248 · cited 1×
“These cognitive deficits are present at the onset of illness, persist for most of patients’ lives without remission, and may precede the development of positive symptoms (Tollefson, 1996; Brewer et al, 2006).”
BackgroundDawson, L. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00265-2 · Cited by 245 · cited 1×
“…levels of DA and acetylcholine in frontal cortex (Liegeois et al, 2002); whereas, 5-HT6 receptor antagonists also increase levels of glutamate (Dawson et al, 2001; Lacroix et al, 2004; Mitchell and Neumaier, 2005; Li et al, 2007) as well as DA and norepinephrine (Lacroix et al, 2004) in the…”
BackgroundCochran, S. M., Kennedy, M., McKerchar, C. E., Steward, L. J., Pratt, J. A., & Morris, B. J. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300031 · Cited by 236 · cited 2×
“However, the face validity of our model is augmented by previous reports of schizophrenia-like pathology, such as decreased parvalbumin expression (Abdul-Monim et al, 2007) and cortical metabolic hypofunction (Cochran et al, 2003) following PCP administration.”
BackgroundMethodHirst, W. D., Stean, T. O., Rogers, D. C., Sunter, D., Pugh, P., Moss, S. F., Bromidge, S. M., Riley, G., Smith, D. R., Bartlett, S., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.09.049 · Cited by 234 · cited 1×
“Thus, inhibition of cholinergic function may interfere with the expression of effects mediated by 5-HT6 receptor antagonism (see Mitchell and Neumaier, 2005; Hirst et al, 2006).”
Background5-HT6 receptors: a novel target for cognitive enhancement
Mitchell, E. S., & Neumaier, J. F. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.001 · Cited by 233 · cited 5×
“Activity at 5-HT6 receptors has been postulated to be important in cognitive dysfunction (Mitchell and Neumaier, 2005) and psychopathology (East et al, 2002), and in the present study, the 5-HT6 antagonist reversed the PCP-induced impairment as did sertindole, while the 5-HT2A receptor antagonist treatment did not imp…”
BackgroundResultInfluentialLectures on Clinical Psychiatry.
(1906) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1906.02510420061028 · Cited by 206
Abdul-Monim, Z., Neill, J. C., & Reynolds, G. P. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107067097 · Cited by 206 · cited 2×
“…we employed the well-validated subchronic phencyclidine (PCP)-administration paradigm (Jentsch and Roth, 1999; Cochran et al, 2003; Egerton et al, 2005; Abdul-Monim et al, 2006, 2007) to produce enduring cognitive deficits similar to those observed in schizophrenia (Javitt and Zukin, 1991).”
BackgroundMethodPDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats
Rodefer, J. S., Murphy, E. R., & Baxter, M. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03937.x · Cited by 199 · cited 1×
“…experiments, we utilized a rodent model of attentional set shifting that is sensitive to the effects of lesions (Birrell and Brown, 2000; Fox et al, 2003), natural aging (Barense et al, 2002), and pharmacological manipulations (Chen et al, 2004; Rodefer et al, 2005; Rodefer and Nguyen, 2006).”
MethodSelf-citationNatesan, S., Reckless, G. E., Nobrega, J. N., Fletcher, P. J., & Kapur, S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300983 · Cited by 192 · cited 1×
“…been shown to induce DA D2 receptor occupancies that correspond to therapeutically effective levels reported previously (Zhang and Bymaster, 1999; Natesan et al, 2006; LTB Brennum, H Lundbeck, unpublished), and induce marked behavioral effects in various animal models of psychosis (for review,…”
BackgroundLectures on clinical psychiatry.
Kraepelin, E. (1904) · doi:10.1037/10789-000 · Cited by 188
Barense, M. D., Fox, M. T., & Baxter, M. G. (2002) · Learning & Memory · doi:10.1101/lm.48602 · Cited by 187 · cited 1×
“…experiments, we utilized a rodent model of attentional set shifting that is sensitive to the effects of lesions (Birrell and Brown, 2000; Fox et al, 2003), natural aging (Barense et al, 2002), and pharmacological manipulations (Chen et al, 2004; Rodefer et al, 2005; Rodefer and Nguyen, 2006).”
MethodEgerton, A., Reid, L., McKerchar, C. E., Morris, B., & Pratt, J. A. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2109-y · Cited by 166 · cited 1×
“In addition, we employed the well-validated subchronic phencyclidine (PCP)-administration paradigm (Jentsch and Roth, 1999; Cochran et al, 2003; Egerton et al, 2005; Abdul-Monim et al, 2006, 2007) to produce enduring cognitive deficits similar to those observed in schizophrenia (Javitt and Zukin,…”
MethodHarvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1888 · Cited by 161 · cited 1×
“…et al, 2004; Remillard et al, 2005; Lee et al, 2007) or slightly effective, as measured by Wisconsin Card Sorting Test (Meltzer and McGurk, 1999; Harvey et al, 2005), and olanzapine produces effects in the same range as risperidone (Meltzer and McGurk, 1999; Bilder et al, 2002; Keefe et al,…”
MethodZhang, W., & Bymaster, F. P. (1999) · Psychopharmacology · doi:10.1007/s002130050834 · Cited by 159 · cited 7×
“It is possible that combined 5-HT2A and DA D2 antagonism of clozapine, olanzapine, and risperidone (Zhang and Bymaster, 1999; Sanchez and Arnt, 2000) can ameliorate deficits in the reversal learning paradigm, while improvement in EDS performance may require additional neurochemical effects, such as…”
BackgroundMethodInfluentialCognitive function in schizophrenic patients.
Robinson, D. S., Roberts, D. L., Smith, J. M., Stringfellow, J., Kaplita, S., Seminara, J. A., & Marcus, R. N. (1996) · PubMed · Cited by 159
Abdul-Monim, Z., Reynolds, G. P., & Neill, J. C. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.01.019 · Cited by 157 · cited 2×
“To our knowledge, the only other broadly characterized model is the short-term operant reversal-learning paradigm (Abdul-Monim et al, 2006).”
BackgroundMethodCognitive Function in Schizophrenia— Do Neuroleptics Make a Difference?
Mortimer, A. M. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00425-x · Cited by 147 · cited 2×
“Depending on the type of cognitive domain measured, second-generation antipsychotics have been reported to produce improvement (Mortimer 1997; Meltzer and McGurk, 1999; Keefe et al, 2007), no effect (Hoff et al, 1996; Meltzer and McGurk, 1999), and impairment (Goldberg et al, 1993).”
BackgroundLacroix, L. P., Dawson, L. A., Hagan, J. J., & Heidbreder, C. A. (2004) · Synapse · doi:10.1002/syn.10288 · Cited by 146 · cited 3×
“…(Liegeois et al, 2002); whereas, 5-HT6 receptor antagonists also increase levels of glutamate (Dawson et al, 2001; Lacroix et al, 2004; Mitchell and Neumaier, 2005; Li et al, 2007) as well as DA and norepinephrine (Lacroix et al, 2004) in the frontal cortex without impacting 5-HT transmission.”
BackgroundMethodLiégeois, J.-F., Ichikawa, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02620-3 · Cited by 145 · cited 1×
“Combined 5-HT2A/DA D2 antagonism can increase extracellular levels of DA and acetylcholine in frontal cortex (Liegeois et al, 2002); whereas, 5-HT6 receptor antagonists also increase levels of glutamate (Dawson et al, 2001; Lacroix et al, 2004; Mitchell and Neumaier, 2005; Li et al, 2007) as well…”
Cognitive function in schizophrenia
Weinberger, D. R., & Gallhofer, B. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199709004-00006 · Cited by 139 · cited 1×
“However, Kraepelin’s characterization of schizophrenia from over a century ago included descriptions of cognitive deficits (Kraepelin, 1904), and these have gained greater attention in the treatment literature during the past decade (Green et al, 2000; Weinberger and Gallhofer, 1997).”
BackgroundHoff, A. L. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00242-6 · Cited by 133 · cited 2×
“Depending on the type of cognitive domain measured, second-generation antipsychotics have been reported to produce improvement (Mortimer 1997; Meltzer and McGurk, 1999; Keefe et al, 2007), no effect (Hoff et al, 1996; Meltzer and McGurk, 1999), and impairment (Goldberg et al, 1993).”
BackgroundFeatherstone, R. E., Rizos, Z., Nóbrega, J. N., Kapur, S., & Fletcher, P. J. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301223 · Cited by 122 · cited 1×
“…pharmacological effects are replicated in another recently developed neurodevelopmental rodent model of schizophrenia, neonatal treatment with the neurotoxin MAM (methylazoxymethanol), which has been demonstrated to produce impairments in attentional set shifting (Featherstone et al, 2007).”
BackgroundNeuroleptic drug effects on cognitive function in schizophrenia
Cleghorn, J. M. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90038-9 · Cited by 118 · cited 1×
“Conventional antipsychotic treatments (eg haloperidol) are reported to lack effect on cognitive deficits (Mortimer, 1997), and to impair some cognitive functions (Cleghorn et al, 1990; Cutmore and Beninger, 1990).”
Background5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats
Hatcher, P. D., Brown, V. J., Tait, D. S., Bate, S. T., Overend, P., Hagan, J. J., & Jones, D. N. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2261-z · Cited by 117 · cited 2×
“…disruption and that have been shown to induce DA D2 receptor occupancies corresponding to therapeutically effective levels (Olsen et al, 2006) or to be effective in relevant mechanistic in vivo models (Zhang and Bymaster, 1999; Sanchez and Arnt, 2000; Hatcher et al, 2005; Wunsch et al, 2006).”
BackgroundResultSkarsfeldt, T. (1996) · Psychopharmacology · doi:10.1007/bf02245612 · Cited by 114 · cited 1×
“In preclinical cognition tests, differential effects of antipsychotics have been reported, with some antipsychotics impairing cognitive function in normal animals, and others apparently having no effect (eg Didriksen, 1995; Skarsfeldt, 1996; Didriksen et al, 2006).”
BackgroundConvergence of cognitive and adaptive decline in late-life schizophrenia
Harvey, P. D., Parrella, M., White, L., Mohs, R. C., Davidson, M., & Davis, K. L. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00109-1 · Cited by 112 · cited 1×
“Unlike psychotic symptoms, cognitive deficits demonstrate a robust inverse association with community functioning and illness outcome (Addington and Addington, 1999; Green, 1996; Harvey et al, 1999).”
BackgroundFox, M. T., Barense, M. D., & Baxter, M. G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-02-00676.2003 · Cited by 104 · cited 2×
“…current experiments, we utilized a rodent model of attentional set shifting that is sensitive to the effects of lesions (Birrell and Brown, 2000; Fox et al, 2003), natural aging (Barense et al, 2002), and pharmacological manipulations (Chen et al, 2004; Rodefer et al, 2005; Rodefer and Nguyen,…”
MethodCentral blockade of muscarinic cholinergic receptors disrupts affective and attentional set‐shifting
Chen, K. C., Baxter, M. G., & Rodefer, J. S. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03548.x · Cited by 97 · cited 2×
“The selective muscarinic cholinergic antagonist scopolamine potently impairs EDS learning in normal control rats using the same experimental procedure (Chen et al, 2004) potentially reflecting nonfrontal cholinergic activity (Eichenbaum et al, 2003).”
MethodSelf-citationEast, S. Z., Burnet, P. W. J., Leslie, R. A., Roberts, J. C., & Harrison, P. J. (2002) · Synapse · doi:10.1002/syn.10097 · Cited by 87 · cited 1×
“Activity at 5-HT6 receptors has been postulated to be important in cognitive dysfunction (Mitchell and Neumaier, 2005) and psychopathology (East et al, 2002), and in the present study, the 5-HT6 antagonist reversed the PCP-induced impairment as did sertindole, while the 5-HT2A receptor antagonist…”
BackgroundDo Clozapine and Risperidone Affect Social Competence and Problem Solving?
Bellack, A. S., Schooler, N. R., Marder, S. R., Kane, J. M., Brown, C. H., & Yang, Y. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.364 · Cited by 80 · cited 2×
“Risperidone has been shown either to be not effective (Bellack et al, 2004; Remillard et al, 2005; Lee et al, 2007) or slightly effective, as measured by Wisconsin Card Sorting Test (Meltzer and McGurk, 1999; Harvey et al, 2005), and olanzapine produces effects in the same range as risperidone…”
BackgroundMethodDidriksen, M. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00242-d · Cited by 76 · cited 1×
“In preclinical cognition tests, differential effects of antipsychotics have been reported, with some antipsychotics impairing cognitive function in normal animals, and others apparently having no effect (eg Didriksen, 1995; Skarsfeldt, 1996; Didriksen et al, 2006).”
BackgroundLi, Z., Huang, M., Prus, A. J., Dai, J., & Meltzer, H. Y. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.060 · Cited by 63 · cited 1×
“…(Liegeois et al, 2002); whereas, 5-HT6 receptor antagonists also increase levels of glutamate (Dawson et al, 2001; Lacroix et al, 2004; Mitchell and Neumaier, 2005; Li et al, 2007) as well as DA and norepinephrine (Lacroix et al, 2004) in the frontal cortex without impacting 5-HT transmission.”
BackgroundR-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram
Sánchez, C., & Kreilgaard, M. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2003.12.001 · Cited by 57 · cited 1×
“On-line sample preparation and liquid chromatography were performed with turbulent flow chromatography (Cohesive Technologies, UK), using a dual column configuration, according to the methodology described previously (Sanchez and Kreilgaard 2004).”
MethodDidriksen, M., Kreilgaard, M., & Arnt, J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.05.021 · Cited by 50 · cited 1×
“In preclinical cognition tests, differential effects of antipsychotics have been reported, with some antipsychotics impairing cognitive function in normal animals, and others apparently having no effect (eg Didriksen, 1995; Skarsfeldt, 1996; Didriksen et al, 2006).”
BackgroundSelf-citationAzorin, J.-M., Strub, N., & Loft, H. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000177020.26311.a7 · Cited by 48 · cited 1×
“…or ‘atypical’ antipsychotics) such as clozapine (Fitton and Heel, 1990), olanzapine (Fulton and Goa, 1997), and sertindole (Kane and Tamminga, 1997; Azorin et al, 2006) have some beneficial effect on negative symptoms and reduced potential to produce extrapyramidal side effects, but these agents…”
BackgroundGallhofer, B., Jaanson, P., Mittoux, A., Tanghøj, P., Lis, S., & Krieger, S. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-990291 · Cited by 48 · cited 4×
“The effect of sertindole on cognitive function has not been investigated extensively; however, a small clinical trial indicates a beneficial effect on some cognitive substrates, including executive function, in individuals diagnosed with schizophrenia (Gallhofer et al, 2007).”
BackgroundResultInfluentialCognition, Drug Treatment, and Functional Outcome in Schizophrenia: A Tale of Two Transitions
Green, M. F. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.992 · Cited by 48 · cited 1×
“Recently, it has been noted that meaningful cognitive enhancement for individuals with schizophrenia will not likely come from traditional medications (Green, 2007) and even instances where positive effects are reported may be due to practice effects (Goldberg et al, 2007).”
BackgroundDo neuroleptics impair learning in schizophrenic patients?
Cutmore, T., & Beninger, R. J. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90035-6 · Cited by 45 · cited 1×
“Conventional antipsychotic treatments (eg haloperidol) are reported to lack effect on cognitive deficits (Mortimer, 1997), and to impair some cognitive functions (Cleghorn et al, 1990; Cutmore and Beninger, 1990).”
BackgroundRémillard, S., Pourcher, E., & Cohen, H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.026 · Cited by 40 · cited 1×
“Risperidone has been shown either to be not effective (Bellack et al, 2004; Remillard et al, 2005; Lee et al, 2007) or slightly effective, as measured by Wisconsin Card Sorting Test (Meltzer and McGurk, 1999; Harvey et al, 2005), and olanzapine produces effects in the same range as risperidone…”
MethodNaltrexone reverses age-induced cognitive deficits in rats
Rodefer, J. S., & Nguyen, T. N. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.005 · Cited by 38 · cited 2×
“In the current experiments, we utilized a rodent model of attentional set shifting that is sensitive to the effects of lesions (Birrell and Brown, 2000; Fox et al, 2003), natural aging (Barense et al, 2002), and pharmacological manipulations (Chen et al, 2004; Rodefer et al, 2005; Rodefer and Nguyen, 2006).”
MethodSelf-citationSertindole in the treatment of psychosis in schizophrenia: efficacy and safety
Tamminga, C. A., Mack, R. J., Granneman, G. R., Silber, C. J., & Kashkin, K. B. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199702001-00005 · Cited by 36 · cited 1×
“In addition, plasma levels of sertindole after the minimal effective dose (1.3 mg/ kg) were within the range of exposures obtained in clinical studies of sertindole (35–100 ng/ml; Tamminga et al, 1997).”
BackgroundInfluentialReceptor profile of antipsychotics
Leysen, J. E. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8448-8_4 · Cited by 35 · cited 2×
“A potential complicating factor to this hypothesis is that, while risperidone is devoid of 5-HT6 receptor antagonism, both clozapine and olanzapine have high 5-HT6 receptor affinities (Leysen, 2000) but did not demonstrate significant effects on EDS performance.”
BackgroundEffects of antipsychotics on cognitive performance in drug-naive schizophrenic patients
Lee, S.-M., Chou, Y.-H., Li, M., Wan, F.-J., & Yen, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.016 · Cited by 34
In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics
Sánchez, C., & Arnt, J. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00012 · Cited by 28 · cited 4×
“We selected dose ranges for compounds that did not produce behavioral disruption and that have been shown to induce DA D2 receptor occupancies corresponding to therapeutically effective levels (Olsen et al, 2006) or to be effective in relevant mechanistic in vivo models (Zhang and Bymaster, 1999; Sanchez and Arnt, 200…”
BackgroundSelf-citationSertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic
Kane, J. M., & Tamminga, C. A. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.11.1729 · Cited by 21 · cited 2×
“…(second-generation or ‘atypical’ antipsychotics) such as clozapine (Fitton and Heel, 1990), olanzapine (Fulton and Goa, 1997), and sertindole (Kane and Tamminga, 1997; Azorin et al, 2006) have some beneficial effect on negative symptoms and reduced potential to produce extrapyramidal side…”
Background
Research works printed but not linked: 1
- Rodefer JS (2006). The effects of antipsychotics on reversing PCP-induced deficits in a rodent attentional set-shifting task. Schizophr Res 81S: 130.
Cited by
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
“…ineffective in reversing the PCP-induced deficit, however sertindole and the selective 5-HT6 (SB-271046) and 5-HT2A (M100907) receptor antagonists did attenuate the PCP-induced impairment (Rodefer et al., 2008), which is similar to our findings using reversal learning paradigm (Idris et al. 2010).”
ResultNeural circuits subserving behavioral flexibility and their relevance to schizophrenia
Floresco, S. B., Zhang, Y., & Enomoto, T. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.001 · Cited by 298
Revel, F. G., Moreau, J.-L., Pouzet, B., Mory, R., Bradaia, A., Buchy, D., Metzler, V, Chaboz, S., Groebke Zbinden, K., Galley, G., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.57 · Cited by 288
Nielsen, R. E., Levander, S., Kjaersdam Telléus, G., Jensen, S. O. W., Østergaard Christensen, T., & Leucht, S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12374 · Cited by 270
Ventral Striatal Dopamine Modulation of Different Forms of Behavioral Flexibility
Haluk, D. M., & Floresco, S. B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.21 · Cited by 195
Metadata
- Authors
- Rodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J.
- Affiliations
- University of Iowa (US)
- Lundbeck (Denmark) (DK)
- Corresponding author
- Rodefer, Joshua S
- ORCID
- Rodefer, Joshua S
- Venue
- Neuropsychopharmacology
- Published
- 2007-12-19
- Volume
- 33
- Issue
- 11
- Pages
- 2657-2666
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2140390949
- Cited by
- 126
- References
- 64
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 7 · 2017: 5 · 2016: 1 · 2015: 13 · 2014: 9 · 2013: 9 · 2012: 7
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- schizophrenia, cognitive impairment, set-shifting, executive function, sertindole, 5-HT6 receptor antagonists, phencyclidine, haloperidol, atypical antipsychotics, risperidone, clozapine, olanzapine, M100907, 5-HT2A receptor antagonist, antimuscarinic activity
- MeSH terms
- Animals, Attention, Imidazoles, Indoles, Male, Phencyclidine, Receptors, Serotonin, Serotonin Antagonists, Antipsychotic Agents, Rats, Long-Evans, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.